Survey: Pharma Industry Ranks UPS, Marken As Top Clinical Trial Logistics Provider
14 March 2017 - 12:00AM
UPS (NYSE: UPS) and Marken are proud to be recognized by
participants in Nice Insight’s 2017 Clinical Supply Chain Logistics
Survey as a top provider in temperature data collection and
management services for clinical trial materials. Survey findings
were released in March of 2017 in Pharma’s Almanac, a quarterly
supplement to the American Pharmaceutical Review.
Nice Insight, the research arm of That’s Nice, A Science Agency,
based in New York City, conducted its first market survey to gauge
the pharmaceutical industry’s perceptions of the most prominent
global supply chain logistics providers. Nice Insight surveyed 320
key healthcare logistics decision-makers at large and midsize
organizations in North America, Europe and Asia. UPS/Marken
consistently scored highest among study respondents across a range
of technical, operational and service capabilities. Fielded and
tabulated just after the announcement and closing of UPS’s
acquisition of Marken, respectively, the combined brands were among
22 top providers of supply chain logistics for the pharma-biotech
industry rated.
“UPS and Marken are honored to be recognized by the industry for
best-in-class service offerings for clinical trials,” says Geoff
Light, UPS president of healthcare logistics strategy. “Improved
health outcomes through sophisticated drugs and vaccines start with
successful trials, and optimized logistics is an integral component
of medical research and development.”
Healthcare logistics is a strategic priority for UPS, and in
2016 it announced an expansion of clinical trial capabilities.
Also, in December of 2016, UPS continued its investment in market
expertise, with the acquisition of Marken. Marken works
closely with its clinical trial clients and investigator sites to
collect and ship drug products, clinical trial materials and
biological samples. As an industry leader, Marken is well-known for
its commitment to hitting milestones, on-time delivery, flexibility
to handle change, regulatory expertise and good understanding of
clients’ needs. Marken’s global network facilitates the growing
demand for direct-to-patient services and reliable handling of cell
and gene therapy materials.
“The explosive growth of cell and gene therapies is a good
example of clinical research that requires a streamlined supply
chain powered by a team experienced in logistics solutions for
complex therapies,” says Wes Wheeler, CEO of Marken. “Marken
appreciates the trust that the pharmaceutical industry puts in our
capabilities, and we will continue to grow and innovate with UPS’s
support to ensure that we remain, together, the global leaders for
this industry.”
Nice Insight created its Clinical Supply Chain Logistics
Survey “to keep our finger on the pulse of market perceptions when
it comes to clinical logistics and data management service
providers,” says Steve Kuehn, That’s Nice LLC executive content
director, and an editor of Pharma’s Almanac. “Shipping clinical
trial supplies involves strict temperature controls, monitoring and
a broad scope of other specialized solutions, and we want to gain
insights into who organizations view as industry supply chain
leaders.”
Survey results will be distributed at the upcoming Drug,
Chemical and Associated Technologies (DCAT) conference to attendees
in the pharmaceutical development and manufacturing sector. The
results will also be shared at Interphex, a pharmaceutical,
biotechnology and medical device event for industry professionals.
Both conferences will be held in March in New York.
About UPS
UPS is a global leader in logistics, offering a broad range of
solutions including transporting packages and freight; facilitating
international trade, and deploying advanced technology to more
efficiently manage the world of business. Headquartered in Atlanta,
UPS serves more than 220 countries and territories worldwide. The
company can be found on the web at ups.com and its corporate
blog can be found at longitudes.ups.com. To get UPS news
direct, visit pressroom.ups.com/RSS or follow @UPS_News.
About UPS Healthcare
UPS provides best-in-class, global supply chain solutions and
compliance expertise to pharmaceutical, biopharma and medical
device companies. UPS has 60+ healthcare-dedicated facilities and 7
million square feet of cGMP- or cGDP-compliant healthcare
distribution space. UPS also maintains the world’s largest network
of field stocking locations with 950 sites. For parcels requiring
strict temperature environments, from CRT to cryogenic, and those
requiring around-the-clock monitoring, UPS has solutions such as
UPS Temperature True™ and UPS Proactive Response™ services.
UPS is committed to expanding its healthcare capabilities including
recent acquisitions of Marken, CEMELOG and Poltraf, to meet the
complex and evolving supply chain needs of the healthcare and life
science sectors. Visit ups.com/healthcare.
About Marken
Marken is a wholly owned subsidiary of UPS. Marken is the
only patient-centric supply chain organization 100% dedicated to
the pharmaceutical and life sciences industries. Marken maintains
the leading position for Direct to Patient services and biological
sample shipments and offers a state-of-the-art GMP-compliant depot
network and logistic hubs in 45 locations worldwide for clinical
trial material storage and distribution. Marken’s more than 720
staff members manage 50,000 drug and biological shipments every
month at all temperature ranges in more than 150 countries.
Additional services such as biological kit production, ancillary
material sourcing, storage and distribution, shipment lane
verification and qualifications, as well as GDP, regulatory and
compliance consultancy add to Marken’s unique position in the
pharma and logistics industry.
David Graves, UPS Public Relations
davidgraves@ups.com
Christine Noble, Marken Marketing
christine.noble@marken.com
United Parcel Service (NYSE:UPS)
Historical Stock Chart
From Mar 2024 to Apr 2024
United Parcel Service (NYSE:UPS)
Historical Stock Chart
From Apr 2023 to Apr 2024